SULFADIAZINE
LOE ApproachingNDAORALTABLET
Approved
Aug 1941
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
SULFADIAZINE by Eli Lilly and Company is clinical pharmacology silver sulfadiazine has broad antimicrobial activity. First approved in 1941.
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Sulfadiazine is a sulfonamide antibiotic originally approved in 1941 by Eli Lilly for oral tablet administration. It is a broad-spectrum small-molecule agent historically used to treat bacterial infections, though specific indications are not detailed in current commercial data. The drug represents one of the earliest systemic antibiotics developed, predating modern antibiotic classes.
$0.781MPart D
LOE ApproachingLow commercial spending and minimal claims volume suggest a declining legacy product with minimal team investment; roles are likely limited to compliance and lifecycle management.
Mechanism of Action
CLINICAL PHARMACOLOGY Silver sulfadiazine has broad antimicrobial activity. It is bactericidal for many gram-negative and gram-positive bacteria as well as being effective against yeast. Results from in vitro testing are listed below. Sufficient data have been obtained to demonstrate that silver…
Indications
Worked on SULFADIAZINE at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.